Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Allakos Inc. (ALLK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/21/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF ALLAKOS INC."
08/18/2023 SC 13D/A Alta Partners VIII, L.P. reports a 3.5% stake in Allakos Inc.
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results SAN CARLOS, Calif., August 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events • Presented preclinical data at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023 highlighting lirentelimab and AK006 mechanisms of action and inhibitory activity on IgE and non-IgE activated mast cells. Key findings of the presentation included: o AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib. o Siglec-6 interacts with ..."
08/02/2023 8-K Quarterly results
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition – AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib – – AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation – SAN CARLOS, Calif., June 12, 2023 -- Allakos Inc. , a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced an oral presentation at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2023. The presentation highlighted preclinical data detailing lirentelimab and AK006 mechanism ..."
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports First Quarter 2023 Financial Results SAN CARLOS, Calif., May 9, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Recent Allakos Events • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis during the first quarter of 2023. • Continued enrollment of a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria during the first quarter of 2023. Upcom..."
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/17/2023 8-K Quarterly results
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results SAN CARLOS, Calif., March 6, 2023 – Allakos Inc. , a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab and AK006. Recent Allakos Events • Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. • Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patien..."
02/14/2023 SC 13G/A Frazier Life Sciences Public Fund, L.P. reports a 5.6% stake in Allakos Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 3.5% stake in Allakos Inc.
01/10/2023 SC 13G/A MILLENNIUM MANAGEMENT LLC reports a 1% stake in ALLAKOS INC.
01/05/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/29/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results SAN CARLOS, Calif., November 7, 2022 – Allakos Inc. , a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events • Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. o Initiated a Phase 2b randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with chronic spontaneous urticaria in the third quarter of 2022. The Phase 2b CSU clinical trial follows positive results from an open-label Phase 2a clinical trial with intravenou..."
10/11/2022 SC 13D New Enterprise Associates 16, L.P. reports a 7.3% stake in Allakos Inc.
09/30/2022 SC 13G Deep Track Capital, LP reports a 5.3% stake in Allakos Inc.
09/29/2022 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5.9% stake in Allakos Inc.
09/28/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
09/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy